115 related articles for article (PubMed ID: 27090681)
1. [Sofosbuvir/ledipasvir is also effective in routine general practice].
Warpakowski A
MMW Fortschr Med; 2016 Apr; 158 Spec No 1():65. PubMed ID: 27090681
[No Abstract] [Full Text] [Related]
2. A combination of ledipasvir and sofosbuvir (Harvoni) for hepatitis C.
Med Lett Drugs Ther; 2014 Nov; 56(1455):111-2. PubMed ID: 25372848
[No Abstract] [Full Text] [Related]
3. Treatment of hepatitis C with 8 weeks of ledipasvir/sofosbuvir: Highly effective in a predominantly black male patient population.
Tang L; Parker A; Flores Y; Dellario M; Dickson C; Amoroso A; Kottilil S; Wilson E
J Viral Hepat; 2018 Feb; 25(2):205-208. PubMed ID: 28984059
[No Abstract] [Full Text] [Related]
4. Administration of crushed ledipasvir-sofosbuvir tablets via gastrostomy button in a patient coinfected with HIV and hepatitis C virus.
Fulco PP; Sterling RK; Lavoie SR
Am J Health Syst Pharm; 2017 Nov; 74(21):1761-1762. PubMed ID: 29070496
[No Abstract] [Full Text] [Related]
5. [LDV/SOF successful in general practice test].
Bischoff M
MMW Fortschr Med; 2016 Jun; 158 Suppl 1():62. PubMed ID: 27259909
[No Abstract] [Full Text] [Related]
6. New-onset cutaneous lichen planus following therapy for hepatitis C with ledipasvir-sofosbuvir.
Scott GD; Rieger KE
J Cutan Pathol; 2016 Apr; 43(4):408-9. PubMed ID: 26816004
[No Abstract] [Full Text] [Related]
7. Aggressive erosive lichen planus associated with hepatitis C responding to sofosbuvir/ledipasvir treatment.
Morgado-Carrasco D; Combalia A; Fustà-Novell X; Mascaró JM; Iranzo P
Indian J Dermatol Venereol Leprol; 2019; 85(3):326-329. PubMed ID: 30860163
[No Abstract] [Full Text] [Related]
8. Shortened 8-Week Course of Sofosbuvir/Ledipasvir Therapy in Adolescents With Chronic Hepatitis C Infection.
Serranti D; Dodi I; Nicastro E; Cangelosi AM; Riva S; Ricci S; Bartolini E; Trapani S; Mastrangelo G; Vajro P; D'Antiga L; Resti M; Indolfi G
J Pediatr Gastroenterol Nutr; 2019 Nov; 69(5):595-598. PubMed ID: 31335836
[TBL] [Abstract][Full Text] [Related]
9. Eight Weeks Treatment With Sofosbuvir/Ledipasvir in a 4-year-old Child With Chronic Hepatitis C Virus Genotype 1 Infection.
Graf Einsiedel H; Christiansen H; Wiegand J
Pediatr Infect Dis J; 2016 Dec; 35(12):1373. PubMed ID: 27832030
[No Abstract] [Full Text] [Related]
10. Cure with ledipasvir/sofosbuvir for chronic hepatitis C virus in an individual with gastric bypass.
Johnson SW; Teachey AL; Valanejad SM; Griffin SM; Weber SF
J Clin Pharm Ther; 2017 Oct; 42(5):624-626. PubMed ID: 28474386
[TBL] [Abstract][Full Text] [Related]
11. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
[TBL] [Abstract][Full Text] [Related]
12. Sofosbuvir/ledipasvir fixed-dose combination for treatment of chronic hepatitis C virus infection in children.
Rizza SA; Nehra V; Temesgen Z
Drugs Today (Barc); 2017 Aug; 53(8):447-451. PubMed ID: 29119149
[TBL] [Abstract][Full Text] [Related]
13. Classical Kaposi's sarcoma concurrent with ledipasvir-sofosbuvir therapy for hepatitis C infection.
Latini A; Orsini D; Ambrifi M; Colafigli M; Zaccarelli M; Cristaudo A
G Ital Dermatol Venereol; 2019 Oct; 154(5):593-594. PubMed ID: 29192474
[No Abstract] [Full Text] [Related]
14. Emerging options for treating hepatitis C infection.
Fantasia HC
Nurs Womens Health; 2015; 19(2):183-7. PubMed ID: 25900589
[TBL] [Abstract][Full Text] [Related]
15. Anti-HCV for porphyria cutanea tarda.
Abdelmaksoud A
Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28133909
[No Abstract] [Full Text] [Related]
16. Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro-resected patient.
Taibi C; Tempestilli M; D'Avolio A; Garbuglia AR; De Nicolò A; Montalbano M; D'Offizi G
J Clin Pharm Ther; 2017 Oct; 42(5):621-623. PubMed ID: 28474408
[TBL] [Abstract][Full Text] [Related]
17. Therapy for hepatitis C--the costs of success.
Hoofnagle JH; Sherker AH
N Engl J Med; 2014 Apr; 370(16):1552-3. PubMed ID: 24725236
[No Abstract] [Full Text] [Related]
18. Safety of pembrolizumab while commencing treatment for hepatitis C with Harvoni (ledipasvir and sofosbuvir).
Menon LL; Chin B; Khattak MA
Intern Med J; 2018 Dec; 48(12):1542-1543. PubMed ID: 30517998
[No Abstract] [Full Text] [Related]
19. [Interferon free recovery for almost all patients].
Einecke D
MMW Fortschr Med; 2015 Mar; 157(4):71. PubMed ID: 25743991
[No Abstract] [Full Text] [Related]
20. Sofosbuvir/ledipasvir as treatment of hepatitis C virus genotype 5 infection: Two case reports.
Chamorro-de-Vega E; Gimenez-Manzorro A; Sanjurjo M;
Med Clin (Barc); 2018 Jul; 151(2):85-86. PubMed ID: 29295791
[No Abstract] [Full Text] [Related]
[Next] [New Search]
